Selected article for: "clinical observation and high flow"

Author: Nigo, Masayuki; Rasmy, Laila; May, Sarah B.; Rao, Aishwarya; Karimaghaei, Sam; Kannadath, Bijun Sai; la Hoz, Alejandro De; Arias, Cesar A.; Li, Liang; Zhi, Degui
Title: Real World Long-term Assessment of The Efficacy of Tocilizumab in Patients with COVID19: Results From A Large De-identified Multicenter Electronic Health Record Dataset in the United States
  • Cord-id: oxwyvlty
  • Document date: 2021_9_29
  • ID: oxwyvlty
    Snippet: Background: Studies have shown conflicting results on the efficacy of tocilizumab (TCZ) for patients with COVID-19, with many confounders of clinical status and limited duration of the observation. Here, we evaluate the real-world long-term efficacy of TCZ in COVID-19 patients. Methods: We conducted a retrospective study of hospitalized adult patients with COVID-19 using a large US-based multicenter COVID-19 database (Cerner Real-World Data; updated in September, 2020). The TCZ group was defined
    Document: Background: Studies have shown conflicting results on the efficacy of tocilizumab (TCZ) for patients with COVID-19, with many confounders of clinical status and limited duration of the observation. Here, we evaluate the real-world long-term efficacy of TCZ in COVID-19 patients. Methods: We conducted a retrospective study of hospitalized adult patients with COVID-19 using a large US-based multicenter COVID-19 database (Cerner Real-World Data; updated in September, 2020). The TCZ group was defined as patients who received at least one dose of the drug. Matching weight (MW) and a propensity score weighting method were used to balance confounding factors. Results: A total of 20,399 patients were identified. 1,510 and 18,899 were in the TCZ and control groups, respectively. After MW adjustment, no statistically significant differences in all-cause mortality were found for the TCZ vs. control group (Hazard Ratio [HR]:0.76, p=0.06). Survival curves suggested a better trend in short-term observation, driven from a subgroup of patients requiring oxygen masks, BIPAP or CPAP. Conclusion: We observed a temporal (early) benefit of TCZ, especially in patients on non-invasive high-flow supplemental oxygen. However, the benefit effects faded with longer observation. The long-term benefits and risks of TCZ should be carefully evaluated with follow-up studies.

    Search related documents:
    Co phrase search for related documents
    • acute progression and logistic regression: 1, 2, 3, 4, 5, 6
    • acute sars cause respiratory syndrome and admission index: 1
    • acute sars cause respiratory syndrome and logistic regression: 1, 2, 3, 4, 5
    • admission day and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • admission day and long term real world: 1
    • admission index and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • logistic regression and long term observation: 1